Crinetics Pharma (CRNX)
NASDAQ:CRNX
Want to see CRNX full AI Analyst Report?
CRNX Stock Chart & Stats
$41.00
-$0.61(-1.22%)
At close: 4:00 PM EST
$41.00
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$25.83 - $57.99
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.27M
Market Cap
$3.69B
Enterprise Value$3.68B
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$47.85M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 11, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.14
Shares Outstanding105,440,210
10 Day Avg. Volume979,435
30 Day Avg. Volume1,270,033
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue203.77
Enterprise Value/Gross Profit206.05
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$88.14Price Target Upside114.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.8
Revenue Forecast (FY)$68.57M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & RunwayA $1.3B liquidity position funding operations into 2030 gives durable financial flexibility to support commercialization, multiple pivotal readouts, and payer expansion without immediate refinancing. This reduces near‑term funding risk and enables strategic pacing of market investments.
Early Commercial Traction And Payer CoverageMeaningful initial product revenues, steady patient additions and rapid reimbursement/coverage gains materially de‑risk commercialization. Durable payer uptake and expanding prescriber base support sustainable revenue growth potential as treatment adoption broadens and formulary placements deepen.
Compelling Clinical Efficacy Supporting ValueRobust efficacy and rapid onset versus comparators create a durable clinical differentiation that strengthens payer negotiations and prescriber preference. Clinically driven value supports pricing power, formulary wins, and potential first‑line adoption, underpinning longer‑term revenue durability.
Bears Say
High Cash Burn And Large Operating LossesSizable negative cash flow and net losses mean the company remains dependent on external financing over the medium term. Persistent high burn narrows the margin for error on the commercial ramp and increases dilution risk if revenue trajectories or trial timelines slip versus plan.
Rising R&D And Elevated Expense BaseSteep and growing R&D plus substantial SG&A imply the company will sustain a high burn profile to fund trials and commercialization. If revenue growth or reimbursement timing disappoints, the elevated expense run rate could force slower program pacing or additional capital raises, diluting equity holders.
Limited Commercial Transparency And Operational ConstraintsLacking detailed form‑to‑paid and conversion metrics reduces visibility into sustainable uptake; operational bottlenecks (appointment capacity at major centers) further cap scalable adoption. These structural uncertainties complicate forecasting and raise execution risk for durable revenue growth.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $25.83 and its highest was $57.99 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $3.69B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Aug 11, 2026 which is in 61 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on May 07, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.22.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 105,440,210 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went down -13.819%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.14 (114.98% Upside)
$88.14 (114.98% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.33%
12-Months-Change
Fundamentals
Return on Equity
-43.96%
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
CRNX Company Deck
CRNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$88.14
▲(114.98% Upside)
Technical Analysis
Ownership Overview
1.92% Insiders
38.41% Mutual Funds
42.87% Other Institutional Investors
1.54% Public Companies and
Individual Investors